BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27450173)

  • 1. Whole-body 18F-FDG PET/CT in patients with multiple myeloma.
    de Bonilla Damiá A; Fernández López R; Paz Coll A; Borrego Dorado I
    Med Clin (Barc); 2017 Apr; 148(7):e37. PubMed ID: 27450173
    [No Abstract]   [Full Text] [Related]  

  • 2. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
    Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle Involvement of Multiple Myeloma Revealed by FDG PET/CT.
    Liang M; Su M; Wang R; Wang W; Fan C
    Clin Nucl Med; 2017 Apr; 42(4):300-302. PubMed ID: 28195903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Multiple Myeloma.
    Murtazaliev S; Rowe SP; Sheikhbahaei S; Werner RA; Sólnes LB
    PET Clin; 2024 Apr; 19(2):249-260. PubMed ID: 38199914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of
    Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
    Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Myeloma Presenting as Disseminated Osteoblastic Lesions With Intense 18F-FDG Uptake on PET/CT.
    Wang Y; Fan Q; Su M
    Clin Nucl Med; 2021 Oct; 46(10):e492-e495. PubMed ID: 33630796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment response evaluation with
    Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
    Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
    Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma.
    Nanni C; Zamagni E
    PET Clin; 2019 Jul; 14(3):383-389. PubMed ID: 31084777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET-CT in Adrenal Multiple Myeloma.
    Choudhury S; Purandare N; Agrawal A; Shah S; Rangarajan V
    Clin Nucl Med; 2018 Sep; 43(9):691-692. PubMed ID: 30015660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Roles of Fluorodeoxyglucose and Sodium Fluoride in Assessment of Multiple Myeloma Patients: Introducing a Novel Method of PET Quantification to Overcome Shortcomings of the Existing Approaches.
    Zadeh MZ; Raynor WY; Seraj SM; Ayubcha C; Kothekar E; Werner T; Alavi A
    PET Clin; 2019 Jul; 14(3):341-352. PubMed ID: 31084774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma.
    Seval GC; Ozkan E; Beksac M
    PET Clin; 2019 Jul; 14(3):369-381. PubMed ID: 31084776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
    Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
    World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuro-Myelomatosis of the Brachial Plexus - An Unusual Site of Disease Visualized by FDG-PET/CT: A Case Report.
    Fukunaga H; Mutoh T; Tatewaki Y; Shimomura H; Totsune T; Terao C; Miyazawa H; Taki Y
    Am J Case Rep; 2017 May; 18():478-481. PubMed ID: 28458390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
    Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
    In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal Superscan on 18F-FDG PET/CT in a Patient With Multiple Myeloma.
    Fu Z; Chen X; Yang X; Li Q
    Clin Nucl Med; 2019 Feb; 44(2):169-170. PubMed ID: 30516669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
    Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of 18F-FDG-PET and 11C-MET-PET in patients with plasma cell malignancy].
    Kobayashi M; Yamashita K; Takaori-Kondo A
    Nihon Rinsho; 2015 Jan; 73(1):74-9. PubMed ID: 25626308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT Demonstrated the Multiple Myeloma From Prostate.
    Cheng A; Liping F; Wang X; Zhao L; Yang J
    Clin Nucl Med; 2016 Apr; 41(4):328-30. PubMed ID: 26562573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.